Companies such as Applied StemCell (U.S.), LUMITOS AG (U.S.), Synthego (U.S.), Thermo Fisher Scientific Inc. (U.S.) and GenScript (China) are major players in CRISPR gene-editing market.
In January 2024, CRISPR Therapeutics AG and Vertex Pharmaceuticals announced the U.S. FDA approval of Casgevy (exagamglogene autotemcel), marking the first-ever approval of a CRISPR-based gene-editing therapy for the treatment of sickle cell disease and transfusion-dependent β-thalassemia. This milestone signifies a transformative breakthrough in genetic medicine, offering a one-time curative approach for patients with severe genetic blood disorders
The countries covered in the CRISPR gene-editing market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.